US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week

SpyGlass Pharma Inc (SGP): IPO Draws Demand as Med-Tech Story Gains Traction

SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>SpyGlass Pharma (SGP US) filed for an IPO on January 16th, targeting a potential February debut to fund its glaucoma drug-delivery platform.</li>
<li>The BIM-IOL System delivers three years of bimatoprost via drug-eluting intraocular lenses during cataract surgery, addressing adherence issues in a $13B U.S. glaucoma market.</li>
<li>Privately backed by top-tier venture investors, SpyGlass has raised ~$200M, holds an exclusive University of Colorado license, and is advancing two Phase 3 registrational trials.</li>
</ul>


SpyGlass Pharma (SGP US) filed for an IPO on January 16th, targeting a potential February debut to fund its glaucoma drug-delivery platform.
The BIM-IOL System delivers three years of bimatoprost via drug-eluting intraocular lenses during cataract surgery, addressing adherence issues in a $13B U.S. glaucoma market.
Privately backed by top-tier venture investors, SpyGlass has raised ~$200M, holds an exclusive University of Colorado license, and is advancing two Phase 3 registrational trials.


SpyGlass Pharma, Inc. (SGP): Peeking at the IPO Prospectus Of Company Transforming Glaucoma Care